Pharmaceutical Preparations · DE · CIK 1326190
Altimmune develops novel therapies for serious liver diseases, including MASH, AUD, and ALD
Comparable business profile · signals at a glance
In the 90 days to Mar 6, 2026: 6 insiders bought $216K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Durso Jerome BenedictPresident and CEO | Buy | 20,000 | $3.54 | $71K |
| Mar 6, 2026 | Weaver Gregory LChief Financial Officer | Buy | 5,000 | $3.54 | $18K |
| Jan 8, 2026 | Pisano WayneDirector | Buy | 5,000 | $4.08 | $20K |
| Jan 5, 2026 | Sohn Catherine A.Director | Buy | 500 | $4.24 | $2K |
| Dec 29, 2025 | Jorkasky DianeDirector | Buy | 527 | $3.80 | $2K |
| Dec 23, 2025 | Gill JohnDirector | Buy | 12,500 | $4.10 | $51K |
| Dec 22, 2025 | Durso Jerome BenedictDirector | Buy | 12,500 | $4.13 | $52K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.